Jim Cramer Discusses These 11 Stocks & President Trump’s Approval Drop

7. Novo Nordisk A/S (NYSE:NVO)

Number of Hedge Fund Holders In Q4 2024: 64

Novo Nordisk A/S (NYSE:NVO) is one of the two primary players in the global weight loss drug market. It makes weight loss drugs such as Wegovy but has struggled to compete with US pharma giant Eli Lilly. More recently, Novo Nordisk A/S (NYSE:NVO)’s stock has come under pressure due to President Trump’s geopolitical decisions. Investors were worried in January whether the firm would be caught in the crosshairs of a dispute surrounding Greenland between the US and Denmark. However, disappointments about its weight loss drugs have ‘weighed’ more heavily on the stock which dipped by 18% in December after disappointing trials. Here’s what Cramer said about Novo Nordisk A/S (NYSE:NVO):

“[on what foreign pharma tariff might mean for Lilly] Right, in meanwhile Novo Nordisk is up, they would be the one that’d be most hurt, they make their stuff overseas. And Eli Lilly would be helped. But the market is not rational. Or doesn’t believe the President. The President, I was watching Frank, like I do every morning, Frank Holland, the Japanese car companies were up. Well this is, I have a source, source in the administration . . .you guys thought about why you’re, you’re not even tariffing all these cars that are coming in from Japan? Next thing you know, say it here, it comes out there, it was a little strange.”